Table 2.
Imaging characteristics in medical treatment and endovascular treatment groups of recent positive acute stroke clinical trials
| MR CLEAN | EXTEND-IA | ESCAPE | SWIFT PRIME | REVASCAT | THERAPY | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical treatment (n=267) |
Endovas cular treatment (n=233) |
Medical treatment (n=35) |
Endovas cular treatment (n=35) |
Medical treatment (n=150) |
Endovas cular treatment (n=165) |
Medical treatment (n=98) |
Endovas cular treatment (n=98) |
Medical Treatmen (n=103) |
Endovas cular Treatment (n=103) |
Medical treatment (n=53) |
Endovas cular treatment (n=55) |
|
|
Site of vessel occlusion |
||||||||||||
| ICA | 80/266 (30%) |
61/233 (26.1%) |
11/35 (31.4%) |
11/35 (31.4%) |
42/150 (28%) |
48/165 (29.1%) |
15/94 (16%) |
17/93 (18.3%) |
41/103 (39.8%) |
45/103 (43.7%) |
12/53 (22.6%) |
18/55 (32.7%) |
| M1 | 165/266 (62%) |
154/233 (66.1%) |
18/35 (51.4%) |
20/35 (57.2%) |
103/150 (68.7%) |
111/165 (67.3%) |
72/94 (76.6%) |
62/93 (66.7%) |
65/103 (63.1%) |
66/103 (64.1%) |
36/53 (67.9%) |
31/55 (56.4%) |
| M2 | 21/266 (8%) |
18/233 (7.8%) |
6/35 (17.2%) |
4/35 (11.4%) |
5/150 (3.3%) |
6/165 (3.6%) |
6/94 (6.4%) |
13/93 (14%) |
8/103 (7.8%) |
10/103 (9.7%) |
5/53 (9.4%) |
6/55 (10.9%) |
| ASPECTS | ||||||||||||
| Mean±SD | 8.4±2.0 | 8.3±1.8 | 9.1±1.0 | 9.2±0.9 | 8.7±1.4 | 8.6±1.4 | 8.5±1.4 | 8.4±1.5 | 7.2±2.1 | 7.4±2.0 | 7.4±1.7 | 7.1±2.1 |
| Median (IQR) |
9 (8–10) | 9 (7–10) | 9 (9–10) | 9 (9–10) | 8 (7–9) | 9 (8–9) | 9 (8–10) | 9 (7–10) | 8 (6–9) | 7 (6–9) | 8 (7–9) | 7.5 (6–9) |
|
Ischemic core volume - mL |
||||||||||||
| Mean±SD | 46±44 | 42±33 | 20±17 | 19±19 | n/a | n/a | 11±11 | 11±16 | n/a | n/a | n/a | n/a |
| Median (IQR) |
32 (10–69) |
36 (15–60) |
18 (4–29) |
12 (4–32) |
n/a | n/a | 9.0 (1–17) |
6.5 (0–14) |
n/a | n/a | n/a | n/a |
|
Perfusion volume - mL |
||||||||||||
| Mean±SD | 112±103 | 141±97 | 116±48 | 105±39 | n/a | n/a | 126±63 | 116±61 | 7.2±2.1 | n/a | n/a | |
| Median (IQR) |
97 (41–181) |
113 (60–190) |
115 (72–158) |
106 (76–137) |
n/a | n/a | 133 (79–162) |
125 (66–149) |
8 (6–9) |
n/a | n/a | |
|
Clot length -mm |
||||||||||||
| Mean±SD | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 15.7±8.7 | 17.3±11.5 |
| Median (IQR) |
n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 14.1 (10.1– 18.6) |
12.9 (9.4– 22.2) |
|
Collateral grade 0 (worst)/1/2/ 3/4 (best) or the ESCAPE trial collateral imaging criteria |
9/72/111 /71 |
17/64/88 /64 |
n/a | n/a | 145 adequate vs 5 poor |
162 adequate vs 3 poor |
n/a | n/a | n/a | n/a | 7/6/10/1 6/6 |
7/9/11/1 1/6 |